(NEXSTAR) – Federal regulators are warning consumers to stop using infant formula that would have sent four children to hospital and could have contributed to a death in one case. An investigation is currently underway.
Consumer complaints about Cronobacter sakazakii and Salmonella Newport infections are currently being investigated, the U.S. Food and Drug Administration announced Thursday. All reported cases allegedly consumed powdered infant formula from the Abbott Nutrition facility in Sturgis, Michigan.
According to the FDA, four cases of infants falling ill (three with Cronobacter and one with salmonella) in three states – Minnesota, Ohio and Texas – have been reported. All four were hospitalized and Cronobacter may have contributed to the death of an infant.
According to the CDC, Cronobacter bacteria can cause serious and life-threatening infections, such as sepsis or meningitis. Cronobacter infections are often serious in infants and can lead to death. Salmonella, a group of bacteria, can cause gastrointestinal illness and fever.
While the company is working with the FDA to initiate a voluntary recall, federal officials are now encouraging consumers to avoid purchasing or using certain formulas from the Michigan plant. Powder formulas affected include Similac, Alimentum and EleCare with the first two digits of the code ranging from 22 to 37; code has K8, SH or Z2; and if the expiry date is 01/04/2022 or a later date.
Below is an image of the code found on one of the affected products.
These products were sold throughout the country.
The FDA says it found several positive results for Cronobacter sakazii from environmental samples taken at the Michigan facility, as well as “adverse inspection observations by FDA investigators.”
If you have used these products and are concerned about your child’s health, the FDA recommends speaking with your healthcare provider. If your child begins to experience symptoms of Cronobacter or Salmonella, tell your health care provider and seek medical attention for your child immediately.
The FDA says the investigation is still ongoing.